Skip to content

Individualized Perioperative Open-lung Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2).

Individualized Perioperative Open-luna Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2). A Comparative, Prospective, Multicenter, Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02776046
Acronym
iPROVE-O2
Enrollment
756
Registered
2016-05-18
Start date
2017-06-01
Completion date
2019-02-28
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperoxia, Postoperative Complication, Surgical Site Infection

Keywords

Oxygen, surgical site infection, postoperative complication, recruitment maneuvers, open lung strategy

Brief summary

The iPROVE-O2 trial aims at comparing the efficacy of high and conventional FiO2 within a perioperative individualized ventilatory strategy to reduce the overall incidence of SSI.

Interventions

High FiO2 with a perioperative open lung strategy

DRUGConventional FiO2

Conventional FiO2 with a perioperative open lung strategy

Sponsors

Hospital La Fe de Valencia
CollaboratorUNKNOWN
Hospital General Universitario de Valencia
CollaboratorOTHER
Hospital de Manises
CollaboratorOTHER
Hospital de Elche
CollaboratorUNKNOWN
Hospital de Villajoyosa
CollaboratorUNKNOWN
Hospital San Pau de Barcelona
CollaboratorUNKNOWN
Hospital Clinic of Barcelona
CollaboratorOTHER
Hospital Germans Tríes i Pujol de Badalona
CollaboratorUNKNOWN
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
CollaboratorOTHER
Hospital Gregorio Marañon de Madrid
CollaboratorUNKNOWN
Hospital Ramón y Cajal de Madrid
CollaboratorUNKNOWN
Hospital Puerta de Hierro de Majalahonda
CollaboratorUNKNOWN
Hospital Universitario Fundación Alcorcón
CollaboratorOTHER
Hospital Virgen del Rocío de Sevilla
CollaboratorUNKNOWN
Hospital Son Espases de Mallorca
CollaboratorUNKNOWN
Hospital Dr. Negrin de la Palmas
CollaboratorUNKNOWN
Hospital Nuestra Señora de la Candelaria de Santa Cruz de Tenerife
CollaboratorUNKNOWN
Hospital de Leon
CollaboratorOTHER_GOV
Hospital POVISA de Vigo
CollaboratorUNKNOWN
Hospital Álvaro Cunqueiro de Vigo
CollaboratorUNKNOWN
Hospital de Albacete
CollaboratorUNKNOWN
Hospital Principe de Asturias de Madrid
CollaboratorUNKNOWN
Hospital Miguel Servet de Zaragoza
CollaboratorUNKNOWN
Hospital General de Ciudad Real
CollaboratorOTHER
Hospital Río Hortega de Valladolid
CollaboratorUNKNOWN
Fundación para la Investigación del Hospital Clínico de Valencia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age not less than 18 * Planned abdominal surgery\> 2 hours. * Signed informed consent for participation in the study.

Exclusion criteria

* Age less than 18 years. * Pregnant or breast-feeding. * Patients with BMI \>35. * Syndrome of moderate or severe respiratory distress: PaO2/FiO2 \< 200 mmHg. * Heart failure: NYHA IV. * Hemodynamic failure: CI \<2.5 L/min/m2 and / or requirements before surgery ionotropic support. * Diagnosis or suspicion of intracranial hypertension (intracranial pressure\> 15 mmHg). * Mechanical ventilation in the last 15 days. * Presence of pneumothorax. Presence of giant bullae on chest radiography or computed tomography (CT). * Patient with preoperatively CPAP. * Participation in another experimental protocol at the time of intervention selection.

Design outcomes

Primary

MeasureTime frame
Surgical site infectionseven postoperative days

Secondary

MeasureTime frame
Systemic complicationsseven postoperative days
Pulmonary complicationsseven postoperative days
Systemic and pulmonary complicationsthirty postoperative days

Countries

Spain

Contacts

Primary ContactCarlos Ferrando, MD, PhD
cafeoranestesia@gmail.com609892732

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026